Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

OncLive’s November Roundup of Key FDA Approvals in Oncology

December 3rd 2024

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

December 2nd 2024

Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.

The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates

December 1st 2024

Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.

The OncFive: Top Oncology Articles for the Week of 11/24

November 30th 2024

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL

November 29th 2024

Hematologic oncologists offer their perspective on the current and potential future standing of CAR T-cell therapies in the relapsed/refractory ALL treatment landscape.

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

November 28th 2024

Dr Shaughnessy discusses the significance of the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Obe-Cel Stands Out in ALL as the Sole FDA-Approved CAR T-Cell Therapy Given Via Split Dosing

November 26th 2024

Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers

November 25th 2024

The FDA has approved an oral solution of imatinib for the treatment of certain leukemias and other cancers.

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

November 21st 2024

Jorge E. Cortes, MD, details how asciminib is improving upon first- and second-generation SOC TKIs in chronic myeloid leukemia.

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management

November 19th 2024

Minoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Dr Awan on Treatment Considerations With Pirtobrutinib in Hematologic Malignancies

November 15th 2024

Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

November 15th 2024

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

November 14th 2024

The FDA has approved nilotinib tablets without mealtime restrictions for select patients with chronic myeloid leukemia.

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

November 14th 2024

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.

Real-World Experience With CAR T Varies From Trials in DLBCL

November 13th 2024

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

November 12th 2024

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy

November 11th 2024

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

The OncFive: Top Oncology Articles for the Week of 11/3

November 9th 2024

Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.